JAK2 and myeloproliferative disorder: MPN HSCs are resistant to killing by conventional chemotherapy, including hydroxyurea, but they are not resistant to drug-induced DNA damage or the expansion of deleterious HSC clones in the presence of JAK2 V617F [183].